Chronic phase chronic myelogenous leukemia

Chronic Phase Chronic Myelogenous Leukemia
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Fatigue (medical), Weight loss, Splenomegaly
Complications	Progression to accelerated phase or blast crisis
Onset	Typically in adulthood
Duration	Indefinite without treatment
Types	N/A
Causes	Genetic mutation (Philadelphia chromosome)
Risks	Age, Radiation exposure
Diagnosis	Complete blood count, Bone marrow biopsy, Cytogenetic analysis
Differential diagnosis	N/A
Prevention	N/A
Treatment	Tyrosine kinase inhibitors, Stem cell transplantation
Medication	N/A
Prognosis	Generally good with treatment
Frequency	Rare
Deaths	N/A

Overview

Chronic Phase Chronic Myelogenous Leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the overproduction of myeloid cells due to a specific genetic mutation known as the Philadelphia chromosome. This phase is the initial stage of CML and is typically the most manageable with treatment.

Pathophysiology

The hallmark of CML is the presence of the Philadelphia chromosome, a result of a translocation between chromosome 9 and chromosome 22, which creates the BCR-ABL fusion gene. This gene encodes a constitutively active tyrosine kinase that leads to uncontrolled cell division and the accumulation of myeloid cells in the bone marrow and peripheral blood.

Clinical Presentation

Patients in the chronic phase of CML may be asymptomatic or present with nonspecific symptoms such as fatigue (medical), weight loss, and night sweats. Physical examination may reveal splenomegaly, which can cause discomfort or pain in the left upper quadrant of the abdomen.

Diagnosis

The diagnosis of chronic phase CML is typically made through a combination of laboratory tests and clinical findings:

• Complete blood count (CBC): This test often shows leukocytosis with a predominance of mature and immature myeloid cells.
• Bone marrow biopsy: This procedure reveals hypercellularity with increased myeloid to erythroid ratio.
• Cytogenetic analysis: This test confirms the presence of the Philadelphia chromosome.
• Polymerase chain reaction (PCR): This sensitive test detects the BCR-ABL fusion gene.

Treatment

The mainstay of treatment for chronic phase CML is the use of tyrosine kinase inhibitors (TKIs), which specifically target the BCR-ABL protein. Commonly used TKIs include:

• Imatinib
• Dasatinib
• Nilotinib

These medications have significantly improved the prognosis of patients with CML, allowing many to achieve long-term remission.

In some cases, stem cell transplantation may be considered, particularly for patients who do not respond to TKIs or who progress to more advanced phases of the disease.

Prognosis

With the advent of TKIs, the prognosis for patients with chronic phase CML has improved dramatically. Many patients achieve a complete cytogenetic response and have a normal life expectancy. However, regular monitoring is essential to detect any signs of disease progression.

Complications

The primary complication of chronic phase CML is progression to the accelerated phase or blast crisis, which are more aggressive and difficult to treat. Monitoring for resistance to TKIs and managing side effects of treatment are also important aspects of care.

Epidemiology

CML is a rare disease, accounting for approximately 15% of all cases of adult leukemia. It is most commonly diagnosed in middle-aged and older adults, with a slight male predominance.

See Also

• Leukemia
• Philadelphia chromosome
• Tyrosine kinase inhibitor

External Links

• [Link to relevant medical resources]

Classification
External resources